V
Vijay Patil
Researcher at Tata Memorial Hospital
Publications - 289
Citations - 2154
Vijay Patil is an academic researcher from Tata Memorial Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 18, co-authored 184 publications receiving 1332 citations. Previous affiliations of Vijay Patil include Homi Bhabha National Institute & Malabar Cancer Centre.
Papers
More filters
Journal ArticleDOI
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Vanita Noronha,Vijay Patil,Amit Joshi,Nandini Menon,Anuradha Chougule,Abhishek Mahajan,Amit Janu,Nilendu Purandare,Rajesh Kumar,Sucheta More,Supriya Goud,Nandkumar Kadam,Nilesh Daware,Atanu Bhattacharjee,Srushti Shah,Akanksha Yadav,Vaishakhi Trivedi,Vichitra Behel,Amit Dutt,Shripad Banavali,Kumar Prabhash +20 more
TL;DR: Adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC.
Journal ArticleDOI
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Vanita Noronha,Amit Joshi,Vijay Patil,Jai Prakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Vedang Murthy,Tejpal Gupta,Anil K. D'Cruz,Shripad Banavali,Prathamesh S. Pai,Pankaj Chaturvedi,Devendra Chaukar,Nikhil Pande,Arun Chandrasekharan,Vikas Talreja,Dilip Harindran Vallathol,Vijayalakshmi Mathrudev,Aparna Manjrekar,Kamesh Maske,Arati Sanjay Bhelekar,Kavita Nawale,Sadhana Kannan,Vikram Gota,Atanu Bhattacharjee,Shubhada Kane,Shashikant Juvekar,Kumar Prabhash +27 more
TL;DR: Once-every-3-weeks cisplatin at 100 mg/m2 resulted in superior LRC, albeit with more toxicity, than did once-a-week cisplinatin at 30 mg/ m2, and should remain the preferred chemoradiotherapy regimen for LAHNSCC in the adjuvant setting.
Journal ArticleDOI
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234
Krisztina M. Papp-Wallace,N.Q. Nguyen,Michael R. Jacobs,Christopher R. Bethel,Melissa D. Barnes,Vijay Kumar,Saralee Bajaksouzian,Susan D. Rudin,Philip N. Rather,Philip N. Rather,Satish Bhavsar,Tadiparthi Ravikumar,Prasad K Deshpande,Vijay Patil,Ravindra D. Yeole,Sachin Bhagwat,Mahesh Vithalbhai Patel,Focco van den Akker,Robert A. Bonomo +18 more
TL;DR: Three novel diazabicyclooctanes, DBOs, zidebactam, and WCK 4234 were synthesized and biochemically characterized against clinically important bacteria and were effective in murine peritonitis and neutropenic lung infection models caused by MDR Acinetobacter baumannii.
Journal ArticleDOI
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
Kanika Bajaj Pahuja,Thong T. Nguyen,Bijay S. Jaiswal,Kumar Prabhash,Tarjani M. Thaker,Kate Senger,Subhra Chaudhuri,Noelyn M. Kljavin,Aju Antony,Sameer Phalke,Prasanna Kumar,Marco Mravic,Eric Stawiski,Derek Vargas,Steffen Durinck,Ravi Gupta,Arati Khanna-Gupta,Sally E. Trabucco,Ethan Sokol,Ryan J. Hartmaier,Ashish Singh,Anuradha Chougule,Vaishakhi Trivedi,Amit Dutt,Vijay Patil,Amit Joshi,Vanita Noronha,James Ziai,S D Banavali,Vedam L. Ramprasad,William F. DeGrado,Raphael Bueno,Natalia Jura,Somasekar Seshagiri +33 more
TL;DR: Structural modeling and analysis showed that the TMD/JMD mutations function by improving the active dimer interface or stabilizing an activating conformation, and it was found that HER2 G660D employed asymmetric kinase dimerization for activation and signaling.
Journal ArticleDOI
Lung cancer in the Indian subcontinent.
TL;DR: Despite numerous advances in recent years in terms of diagnostic methods, molecular changes, and therapeutic interventions, the outcomes of the lung cancer patients remain poor; hence, a better understanding of the risk factors may impact the preventive measures to be implemented at the community level.